Literature DB >> 21212154

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis.

Anna Lünemann1, Björn Tackenberg, Tracy DeAngelis, Rosa Barreira da Silva, Brady Messmer, Liliana D Vanoaica, Aaron Miller, Brian Apatoff, Fred D Lublin, Jan D Lünemann, Christian Münz.   

Abstract

NK cells are multicompetent lymphocytes of the innate immune system with a central role in host defense and immune regulation. Studies in experimental animal models of multiple sclerosis (MS) provided evidence for both pathologic and protective effects of NK cells. Humans harbor two functionally distinct NK-cell subsets exerting either predominantly cytotoxic (CD56(dim)CD16(+)) or immunoregulatory (CD56(bright)CD16(-)) functions. We analyzed these two subsets and their functions in the peripheral blood of untreated patients with relapsing-remitting MS compared with healthy blood donors. While ex vivo frequencies of CD56(bright)CD16(-) and CD56(dim)CD16(+) NK cells were similar in patients and controls, we found that cytokine-driven in vitro accumulation and IFN-γ production of CD56(bright)CD16(-) NK cells but not of their CD56(dim)CD16(+) counterparts were substantially diminished in MS. Impaired expansion of CD56(bright)CD16(-) NK cells was cell intrinsic because the observed effects could be reproduced with purified NK cells in an independent cohort of patients and controls. In contrast, cytolytic NK-cell activity toward the human erythromyeloblastoid leukemia cell line K562, the allogeneic CD4(+) T cell line CEM and allogeneic primary CD4(+) T-cell blasts was unchanged. Thus, characteristic functions of CD56(bright)CD16(-) NK cells, namely cytokine-induced NK cell expansion and IFN-γ production, are compromised in the NK cell compartment of MS patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212154      PMCID: PMC3030728          DOI: 10.1093/intimm/dxq463

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  49 in total

Review 1.  The role of natural killer cells in curbing neuroinflammation.

Authors:  Benjamin M Segal
Journal:  J Neuroimmunol       Date:  2007-09-29       Impact factor: 3.478

2.  NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha.

Authors:  Fabienne Brilot; Till Strowig; Susanne M Roberts; Frida Arrey; Christian Münz
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 3.  Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity.

Authors:  Till Strowig; Fabienne Brilot; Christian Münz
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

4.  Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses.

Authors:  Rafael S Grajewski; Anna M Hansen; Rajeev K Agarwal; Mitchell Kronenberg; Stephane Sidobre; Shao Bo Su; Phyllis B Silver; Moriya Tsuji; Richard W Franck; Anne P Lawton; Chi-Chao Chan; Rachel R Caspi
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.

Authors:  Cristina Cerboni; Alessandra Zingoni; Marco Cippitelli; Mario Piccoli; Luigi Frati; Angela Santoni
Journal:  Blood       Date:  2007-04-03       Impact factor: 22.113

6.  Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells.

Authors:  Philip L De Jager; Elizabeth Rossin; Saumyadipta Pyne; Pablo Tamayo; Linda Ottoboni; Vissia Viglietta; Mira Weiner; Dulce Soler; Elena Izmailova; Lauren Faron-Yowe; Carmeline O'Brien; Sam Freeman; Susana Granados; Alex Parker; Ronenn Roubenoff; Jill P Mesirov; Samia J Khoury; David A Hafler; Howard L Weiner
Journal:  Brain       Date:  2008-06-21       Impact factor: 13.501

7.  Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.

Authors:  Paolo Carrega; Barbara Morandi; Roberta Costa; Guido Frumento; Giuseppe Forte; Giuseppe Altavilla; Giovanni Battista Ratto; Maria Cristina Mingari; Lorenzo Moretta; Guido Ferlazzo
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

8.  Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition.

Authors:  Anna Lünemann; Jan D Lünemann; Susanne Roberts; Brady Messmer; Rosa Barreira da Silva; Cedric S Raine; Christian Münz
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.

Authors:  M Saraste; H Irjala; L Airas
Journal:  Neurol Sci       Date:  2007-06-30       Impact factor: 3.307

10.  Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma.

Authors:  Till Strowig; Fabienne Brilot; Frida Arrey; Gwenola Bougras; Dolca Thomas; William A Muller; Christian Münz
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

View more
  11 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 2.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

Authors:  Heinz Wiendl; Catharina C Gross
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

4.  Innate immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1).

Authors:  Pascal F Durrenberger; Anna Ettorre; Fatemah Kamel; Louise V Webb; Malcolm Sim; Richard S Nicholas; Omar Malik; Richard Reynolds; Rosemary J Boyton; Daniel M Altmann
Journal:  J Neuroinflammation       Date:  2012-01-02       Impact factor: 8.322

Review 5.  Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Authors:  Gabriel Arellano; Payton A Ottum; Lilian I Reyes; Paula I Burgos; Rodrigo Naves
Journal:  Front Immunol       Date:  2015-09-29       Impact factor: 7.561

Review 6.  The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Samuel S Duffy; Justin G Lees; Gila Moalem-Taylor
Journal:  Mult Scler Int       Date:  2014-10-12

Review 7.  The Role of Natural Killer Cells in Autoimmune Diseases.

Authors:  Umut Can Kucuksezer; Esin Aktas Cetin; Fehim Esen; Ilhan Tahrali; Nilgun Akdeniz; Metin Yusuf Gelmez; Gunnur Deniz
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

8.  NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.

Authors:  Josefine Ruder; Jordan Rex; Simon Obahor; María José Docampo; Antonia M S Müller; Urs Schanz; Ilijas Jelcic; Roland Martin
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 9.  Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis.

Authors:  Océane Perdaens; Vincent van Pesch
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

10.  SHP-1 phosphatase is a critical regulator in preventing natural killer cell self-killing.

Authors:  Sajid Mahmood; Namita Kanwar; Jimmy Tran; Man-Li Zhang; Sam K P Kung
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.